Sign Out
Sitagliptin + Metformin HCl is indicated as initial therapy in patents with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control.
Sitagliptin + Metformin HCl is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patents already being treated with the combination of sitagliptin and metformin.
Sitagliptin + Metformin HCl is indicated as part of triple combination therapy with a sulfonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: sitagliptin, metformin, or sulfonylurea.
Sitagliptin + Metformin HCl is indicated as part of triple combination therapy with a PPARγ agonist (i.e., thiazolidinediones) as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: sitagliptin, metformin, or a PPARγ agonist.
Sitagliptin + Metformin HCl is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve control in combination with insulin.
